CYTOKINETICS INCORPORATED - COMMON STOCK

Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

06 Sep 2023 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Sep 2023 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Reports Second Quarter 2023 Financial Results

03 Aug 2023 15:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: CYTOKINETICS INCORPORATED - COMMON STOCK

02 Aug 2023 08:57:28 By NetDania Notify

Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

01 Aug 2023 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Announce Second Quarter Results on August 3, 2023

27 Jul 2023 15:00:20 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: CYTOKINETICS INCORPORATED - COMMON STOCK

26 Jul 2023 08:45:07 By NetDania Notify

NetDania - New 12 months Low: CYTOKINETICS INCORPORATED - COMMON STOCK

24 Jul 2023 09:22:12 By NetDania Notify

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jul 2023 15:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: CYTOKINETICS INCORPORATED - COMMON STOCK

03 Jul 2023 08:45:46 By NetDania Notify

NetDania - New 12 months Low: CYTOKINETICS INCORPORATED - COMMON STOCK

27 Jun 2023 08:46:03 By NetDania Notify

NetDania - New 12 months Low: CYTOKINETICS INCORPORATED - COMMON STOCK

26 Jun 2023 14:25:49 By NetDania Notify

Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

20 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

02 Jun 2023 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in Upcoming Investor Conferences

01 Jun 2023 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress

20 May 2023 09:30:56 By Nasdaq GlobeNewswire

Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress

15 May 2023 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586

11 May 2023 06:30:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in the JMP Securities Life Sciences Conference

08 May 2023 15:00:00 By Nasdaq GlobeNewswire

Cytokinetics Reports First Quarter 2023 Financial Results

04 May 2023 15:00:00 By Nasdaq GlobeNewswire